Pfizer says testing trials have shown its COVID-19 vaccine is 100 percent effective in children aged 12 to 15 years old, paving the way for them to seek US emergency use authorization in weeks. The trial involved just 2,260 children - a fraction of the size of the adult trial, which involved more than 40,000 people. The company announced on Wednesday that in a Phase 3 trial of children between the ages of 12 and 15, the vaccine 'demonstrated 100 percent efficacy and robust antibody responses'. Researchers reported high levels of virus-fighting antibodies, somewhat higher than were seen in studies of young adults. Results also are expected soon from a US study of Moderna's vaccine in 12- to 17-year-olds.

Source: Daily Mail March 31, 2021 10:54 UTC